Navigation Links
MedImmune to present 4 abstracts on RSV and influenza at 47TH Annual IDSA Meeting
Date:10/30/2009

PHILADELPHIA, P.A., October 30, 2009 MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

"MedImmune is dedicated to conducting ground-breaking research on the prevention of respiratory syncytial virus (RSV) and influenza in children," said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. "We believe the data being presented at the conference may help advance innovative healthcare solutions for these important causes of respiratory infections in children."

MedImmune abstracts to be presented at IDSA on RSV include:

  • Prophylaxis Utilizing Nebulized Motavizumab, a Monoclonal Antibody Against Fusion Protein of Respiratory Syncytial Virus (RSV) Zhang J, et al. Poster Session: October 30, 2009; 12:30 2:00 PM; Poster Hall A / Poster # 608

    BACKGROUND: Respiratory syncytial virus (RSV) infection is the primary cause of pneumonia and bronchiolitis in young children, and also causes disease in older adults. This study evaluated the prophylactic use of nebulized motavizumab, an investigational anti-RSV humanized monoclonal antibody against RSV fusion protein, in cotton rats. The findings suggest that prophylaxis with nebulized motavizumab may inhibit RSV infection and spread in the lungs and may provide an alternative to the current intramuscular antibody delivery.

    MedImmune abstracts to be presented at IDSA on influenza include:

  • A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine Use in Unapproved Children Less Than 59 Months of Age Tennis P, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1179

    BACKGROUND: In September 2007, the approval of live attenuated influenza vaccine (LAIV) was expanded for use in children between 24 and 59 months in age. The vaccine was not approved for use in children younger than 24 months, or for use in children with asthma or recurrent wheezing, or those with altered immunocompetence. This study evaluates the usage and safety of the vaccine in those patient populations younger than 59 months of age that were not in the approved indication. The study found that healthcare providers appear to be complying with the indications for the use of LAIV in children <5 years, and no adverse safety outcomes were detected in the small number of children in unapproved groups who received the vaccine.

  • Whole Genome Transcriptional Analysis of the Early Immune Responses Induced by Live Attenuated and Inactivated Influenza Vaccines in Young Children Zhu W, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1181

    BACKGROUND: This study examined the early genomic immune response to live attenuated and inactivated vaccines in previously unvaccinated children 12 to 35 months of age. Among LAIV recipients, an increase in interferon (a natural anti-viral immune protein) production was seen, which may partly explain previous clinical study observations of LAIV-induced protection against illness in the first 2 weeks after administration.

  • Influenza-Associated Antibiotic Use in Children Receiving Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine Belshe R, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1180

    BACKGROUND: Influenza illness in children commonly results in the unnecessary use of prescription antibiotics. This analysis evaluated the efficacy of live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) in preventing antibiotic use in children ranging from six months to 17 years in age. Overall, there was less influenza-associated antibiotic use in LAIV recipients due to a lower rate of culture-confirmed influenza with LAIV.


'/>"/>

Contact: Tor Constantino
301-398-5801
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition
2. MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
3. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
4. MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
5. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
6. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
7. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
8. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
9. MedImmune Expands Scientific and Engineering Leadership
10. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
11. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Japanese Zen ... Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on ... mat art pieces, such as Zen Kodo mat. Wanderlust , one of the ...
(Date:9/21/2017)... Boulder, CO (PRWEB) , ... September 21, 2017 ... ... Education Interview of the Month, Lewis and Clark College Emeritus Professor of Education ... Associate Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced ... Aligner clinical and commercial support services market) has entered into an agreement on ... Australia. , The PGSD is the first private Dental School to launch ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot ... Vaginas.” The goal is to ignite conversation via social media and word-of-mouth regarding ... brand has declared September “Humans with Vaginas” month, releasing a video celebrating the ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: